



## Traverse Therapeutics to Participate at Upcoming Investor Conferences

2025-11-04

SAN DIEGO--(BUSINESS WIRE)-- Traverse Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

**Guggenheim's 2nd Annual Healthcare Innovation Conference**  
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET

**Stifel 2025 Healthcare Conference**  
Wednesday, November 12, 2025

**TD Cowen Immunology & Inflammation Summit**  
Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET

**Jefferies Global Healthcare Conference**  
Presenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)

**8th Annual Evercore Healthcare Conference**  
Presenting on Tuesday, December 2, 2025, at 10:50 a.m. ET

**Piper Sandler 37th Annual Healthcare Conference**  
Wednesday, December 3, 2025

Live webcasts of the presentations will be accessible on the Investor page of Traverse's website at [ir.traverse.com/events-and-presentations](https://ir.traverse.com/events-and-presentations). Replays will be available for up to 30 days following each event.

### About Traverse Therapeutics

At Traverse Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit [traverse.com](https://traverse.com).

Investors:  
888-969-7879  
[IR@traverse.com](mailto:IR@traverse.com)

Media:  
888-969-7879  
[mediarelations@traverse.com](mailto:mediarelations@traverse.com)

Source: Traverse Therapeutics, Inc.